Unusual length polymorphism in human steroid 5α-reductase type 2 gene (SRD5A2)DAVIS, D. L; RUSSELL, D. W.Human molecular genetics (Print). 1993, Vol 2, Num 6, issn 0964-6906, p. 820Article

Natural mutagenesis study of the human steroid 5α-reductase 2 isozymeWIGLEY, W. C; PRIHODA, J. S; MOWSZOWICZ, I et al.Biochemistry (Easton). 1994, Vol 33, Num 5, pp 1265-1270, issn 0006-2960Article

V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. CommentaryNAM, R. K; TOI, A; PLATZ, Elizabeth A et al.Urology (Ridgewood, NJ). 2001, Vol 57, Num 1, pp 199-205, issn 0090-4295Article

Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: Implications for finasteridetherapy of prostate carcinomaJUN LUO; DUNN, Thomas A; EWING, Charles M et al.The Prostate. 2003, Vol 57, Num 2, pp 134-139, issn 0270-4137, 6 p.Article

A prevalent missense substitution that modulates activity of prostatic steroid 5α-reductaseMAKRIDAKIS, N; ROSS, R. K; PIKE, M. C et al.Cancer research (Baltimore). 1997, Vol 57, Num 6, pp 1020-1022, issn 0008-5472Article

Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British menALLEN, Naomi E; REICHARDT, Juergen K. V; NGUYEN, Hannah et al.Cancer epidemiology, biomarkers & prevention. 2003, Vol 12, Num 6, pp 578-581, issn 1055-9965, 4 p.Article

Association of SRD5A2 genotype and pathological characteristics of prostate tumorsJAFFE, J. M; MALKOWICZ, S. B; WALKER, A. H et al.Cancer research (Baltimore). 2000, Vol 60, Num 6, pp 1626-1630, issn 0008-5472Article

Evidence for an association between the SRD5A2 (type II steroid 5α-reductase) locus and prostate cancer in Italian patientsMARGIOTTI, K; SANGIUOLO, F; NOVELLI, G et al.Disease markers. 2000, Vol 16, Num 3-4, pp 147-150, issn 0278-0240Article

Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USAMAKRIDAKIS, N. M; ROSS, R. K; PIKE, M. C et al.Lancet (British edition). 1999, Vol 354, Num 9183, pp 975-978, issn 0140-6736Article

Genetic variability of the human SRD5A2 gene: implications for prostate cancer riskREICHARDT, J. K. V; MAKRIDAKIS, N; HENDERSON, B. E et al.Cancer research (Baltimore). 1995, Vol 55, Num 18, pp 3973-3975, issn 0008-5472Article

Association of V89L SRD5A2 polymorphism with prostate cancer development in a Japanese populationLI, Zhenhua; HABUCHI, Tomonori; MITSUMORI, Kenji et al.The Journal of urology. 2003, Vol 169, Num 6, pp 2378-2381, issn 0022-5347, 4 p.Article

Polymorphisms in the androgen receptor and type II 5α-reductase genes and prostate cancer prognosisSHIBATA, Atsuko; GARCIA, Maria Isabel; IONA CHENG et al.The Prostate. 2002, Vol 52, Num 4, pp 269-278, issn 0270-4137Article

The steroid 5α-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian womenSPURDLE, Amanda B; HOPPER, John L; XIAOQING CHEN et al.Cancer epidemiology, biomarkers & prevention. 2001, Vol 10, Num 12, pp 1287-1293, issn 1055-9965Article

Sex steroid hormones and genetic susceptibility to breast and prostate cancerFEIGELSON, H. S; ROSS, R. K; YU, M. C et al.Drug metabolism reviews (Softcover ed.). 1998, Vol 30, Num 2, pp 421-434, issn 0360-2532Conference Paper